Fernando Martínez-Galan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fernando Martínez-Galan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Juan Manuel Irache
University of Navarra
2 shared publications M.A. Campanero
2 shared publicationsAndrea San-Martín
Department of Plastic, Aesthetic and Reconstructive Surgery, Clínica Universidad de Navarra, University of Navarra, Pío XII 36, Pamplona, Spain
1 shared publication- Bernardo Hontanilla
Department of Plastic, Aesthetic and Reconstructive Surgery, Clinica Universidad de Navarra, Pamplona, Spain
1 shared publication - Carlos Gamazo
Department of Microbiology and Parasitology, Navarra Medical Research Institute (IdiSNA), University of Navarra, 31008 Pamplona, Spain
1 shared publication I. Goñi
1 shared publication
Latest Publications
- 23 February 2010
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 34 (4) , 430-437
Effect of the Inhibitor Peptide of the Transforming Growth Factor β (p144®) in a New Silicone Pericapsular Fibrotic Model in Pigs
Background Capsular contracture is the most common complication associated with silicone prostheses. It may take the form of anything from slight hardening to obvious deformity. The role of transforming growth factor β (TGF-β) in the scar physiopathology of any fibrotic process has been demonstrated. The effects of inhibition of TGF-β have also been demonstrated in experimental models of fibrosis, which opens the way for new therapeutic alternatives in the treatment of capsular contracture. The aim of this study was to evaluate periprosthetic fibrosis with a newly synthesized TGF-β peptide inhibitor (p144®). Methods Three experimental groups were formed: Group I, subcutaneous and submuscular textured silicone prostheses were left untreated; Group 2, the prostheses were left after being immersed in the vehicle; Group 3, the same protocol was followed as in Group 2, but the solution contained the vehicle with the inhibitor peptide of TGF-β, p144 (15 mg/prosthesis). The animals were sacrificed 24 weeks after implantation, and the capsules were assessed both macroscopically and histologically. Results The results obtained showed that the inhibition of capsular thickness and soluble collagen content in pericapsular fibrosis did not significantly decrease in the group of animals treated with the TGF-β inhibitor peptide in comparison with control cases. Conclusions We detected no statistically significant reduction in fibrosis in the periprosthetic capsule after treating the implants with the inhibitor peptide p144, but we feel that the influence of trauma around the prosthesis is critical in impeding the antifibrotic activity of the inhibitor peptide.
- 23 February 2010
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 34 (4) , 430-437
Effect of the Inhibitor Peptide of the Transforming Growth Factor β (p144®) in a New Silicone Pericapsular Fibrotic Model in Pigs
Background Capsular contracture is the most common complication associated with silicone prostheses. It may take the form of anything from slight hardening to obvious deformity. The role of transforming growth factor β (TGF-β) in the scar physiopathology of any fibrotic process has been demonstrated. The effects of inhibition of TGF-β have also been demonstrated in experimental models of fibrosis, which opens the way for new therapeutic alternatives in the treatment of capsular contracture. The aim of this study was to evaluate periprosthetic fibrosis with a newly synthesized TGF-β peptide inhibitor (p144®). Methods Three experimental groups were formed: Group I, subcutaneous and submuscular textured silicone prostheses were left untreated; Group 2, the prostheses were left after being immersed in the vehicle; Group 3, the same protocol was followed as in Group 2, but the solution contained the vehicle with the inhibitor peptide of TGF-β, p144 (15 mg/prosthesis). The animals were sacrificed 24 weeks after implantation, and the capsules were assessed both macroscopically and histologically. Results The results obtained showed that the inhibition of capsular thickness and soluble collagen content in pericapsular fibrosis did not significantly decrease in the group of animals treated with the TGF-β inhibitor peptide in comparison with control cases. Conclusions We detected no statistically significant reduction in fibrosis in the periprosthetic capsule after treating the implants with the inhibitor peptide p144, but we feel that the influence of trauma around the prosthesis is critical in impeding the antifibrotic activity of the inhibitor peptide.
- 16 October 2008
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 9 (4) , 1063-1069
Stability of Poly(ε-caprolactone) Microparticles Containing Brucella ovis Antigens as a Vaccine Delivery System Against Brucellosis
In previous works, our research group has successfully proved the use of subcellular vaccines based on poly(ε-caprolactone) (PEC) microparticles containing an antigenic extract of Brucella ovis (HS) against experimental brucellosis in both mice and rams. However, the successful exploitation of pharmaceutical products, and therefore of this product as veterinary vaccine, requires preservation of both biological activity and native structure in all steps of development from purification to storage. In this context, we have carried out an accelerated stability study to evaluate the relative stability of HS when loading in PEC microparticles. For this purpose, freeze-dried microparticles were stored at 40 ± 1°C and 75% RH as a preliminary analysis of a stability testing. The results showed that both physico-chemical (size, morphology, antigen content, release profile) and biological (integrity and antigenicity of the HS) properties were preserved after 6 months of storage. On the contrary, after 1 year of storage, the HS release profile was dramatically affected probably due to a progressive loss of the polymer microstructure. In addition, the degradation and loss of the antigenicity of the HS components was also evident by SDS-PAGE and immunoblotting analysis. In fact, after 12 months of storage, only the integrity and antigenicity of two of the major protective proteins of the HS antigenic complex were preserved.
- 16 October 2008
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 9 (4) , 1063-1069
Stability of Poly(ε-caprolactone) Microparticles Containing Brucella ovis Antigens as a Vaccine Delivery System Against Brucellosis
In previous works, our research group has successfully proved the use of subcellular vaccines based on poly(ε-caprolactone) (PEC) microparticles containing an antigenic extract of Brucella ovis (HS) against experimental brucellosis in both mice and rams. However, the successful exploitation of pharmaceutical products, and therefore of this product as veterinary vaccine, requires preservation of both biological activity and native structure in all steps of development from purification to storage. In this context, we have carried out an accelerated stability study to evaluate the relative stability of HS when loading in PEC microparticles. For this purpose, freeze-dried microparticles were stored at 40 ± 1°C and 75% RH as a preliminary analysis of a stability testing. The results showed that both physico-chemical (size, morphology, antigen content, release profile) and biological (integrity and antigenicity of the HS) properties were preserved after 6 months of storage. On the contrary, after 1 year of storage, the HS release profile was dramatically affected probably due to a progressive loss of the polymer microstructure. In addition, the degradation and loss of the antigenicity of the HS components was also evident by SDS-PAGE and immunoblotting analysis. In fact, after 12 months of storage, only the integrity and antigenicity of two of the major protective proteins of the HS antigenic complex were preserved.
- 30 September 2007
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 32 (1) , S17
Lyophilization of adenoviral vectors for gene therapy
- 30 September 2007
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 32 (1) , S17
Lyophilization of adenoviral vectors for gene therapy
- 1 January 2005
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 15 (2) , 121-127
Encapsulation of ganciclovir in albumin nanoparticles enhances the thymidine kinase suicide gene therapy
- 1 January 2005
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 15 (2) , 121-127
Encapsulation of ganciclovir in albumin nanoparticles enhances the thymidine kinase suicide gene therapy